Various approaches to such protein redesign have drawbacks. Traditional methods include time-consuming trial and error efforts, and many models in the emerging field ...
This is my tenth Ligand (LGND) article, following my most recent 06/2025 "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward". In Powers Forward, I rated Ligand as a "Buy". It has since ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results